GO:0047323 [3-methyl-2-oxobutanoate dehydrogenase (acetyl-transferring)] kinase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0047323 describes the kinase activity that phosphorylates the E1 alpha subunit of the branched-chain alpha-ketoacid dehydrogenase complex (BCKDH), thereby inactivating the complex.
• This activity is catalyzed by BCKDK (branched-chain ketoacid dehydrogenase kinase), a mitochondrial protein kinase that belongs to a unique family of alpha-ketoacid dehydrogenase kinases.
• BCKDK phosphorylates BCKDH at specific serine residues, shutting down the oxidative decarboxylation of branched-chain amino acids (BCAAs).
• The kinase is regulated by metabolic signals, including alpha-ketoisovalerate, which stimulates related kinases such as pyruvate dehydrogenase kinase, suggesting a broader regulatory network.
• BCKDK is essential for embryonic development and TCA cycle regulation, as it controls pyruvate dehydrogenase complex activity when PDK family members are absent.
• Dysregulation of BCKDK and BCKDH is linked to maple syrup urine disease, cancer, and neurological disorders, making GO:0047323 a target for therapeutic intervention.
Description
The Gene Ontology (GO) term GO:0047323, [3-methyl-2-oxobutanoate dehydrogenase (acetyl-transferring)] kinase activity, represents a molecular function that is critical for the regulation of branched-chain amino acid (BCAA) catabolism. This kinase activity is responsible for phosphorylating the E1 alpha subunit of the branched-chain alpha-ketoacid dehydrogenase complex (BCKDH), the rate-limiting enzyme in BCAA degradation. By catalyzing this phosphorylation event, the kinase inactivates BCKDH, thereby controlling the flux of BCAAs into the tricarboxylic acid (TCA) cycle and influencing energy homeostasis. The enzyme responsible for this activity, BCKDK, is a member of the mitochondrial alpha-ketoacid dehydrogenase kinase family, which also includes pyruvate dehydrogenase kinase (PDK). Understanding GO:0047323 is essential for researchers studying metabolic regulation, mitochondrial function, and diseases such as maple syrup urine disease and cancer, where BCAA metabolism is often perturbed.
[3-methyl-2-oxobutanoate dehydrogenase (acetyl-transferring)] kinase activity At A Glance
| GO ID | GO:0047323 |
|---|---|
| GO term | [3-methyl-2-oxobutanoate dehydrogenase (acetyl-transferring)] kinase activity |
| Ontology | molecular_function |
| Synonym | BCKD kinase activity; branched-chain alpha-ketoacid dehydrogenase kinase activity; STK2 |
| Major function | Phosphorylation and inactivation of the BCKDH complex, regulating BCAA catabolism |
| Reaction | ATP + L-seryl-[3-methyl-2-oxobutanoate dehydrogenase] = ADP + H+ + O-phospho-L-seryl-[3-methyl-2-oxobutanoate dehydrogenase] |
| Enzyme family | Mitochondrial alpha-ketoacid dehydrogenase kinase family |
| Substrate | E1 alpha subunit of BCKDH (3-methyl-2-oxobutanoate dehydrogenase) |
| Cofactor | ATP (as phosphate donor) |
What Is GO:0047323?
GO:0047323 is defined as the catalysis of the reaction: ATP + L-seryl-[3-methyl-2-oxobutanoate dehydrogenase] = ADP + H+ + O-phospho-L-seryl-[3-methyl-2-oxobutanoate dehydrogenase]. In simpler terms, it is the enzyme activity that transfers a phosphate group from ATP to a specific serine residue on the E1 alpha subunit of the BCKDH complex, using the dehydrogenase as a substrate. This phosphorylation event is a key regulatory mechanism that inhibits the dehydrogenase's catalytic activity, thereby controlling the rate of BCAA oxidation.
Why Is [3-methyl-2-oxobutanoate dehydrogenase (acetyl-transferring)] kinase activity Important in Cell Biology?
GO:0047323 is important because it governs the activity of the branched-chain alpha-ketoacid dehydrogenase complex, a critical node in BCAA metabolism. Dysregulation of this kinase activity leads to altered BCAA levels, which are associated with metabolic disorders, neurological dysfunction, and cancer. Moreover, BCKDK has been shown to regulate the TCA cycle through pyruvate dehydrogenase complex in the absence of PDK family members during embryonic development, highlighting its broader role in mitochondrial energy metabolism. Thus, understanding GO:0047323 provides insights into fundamental metabolic control and potential therapeutic targets.
• Regulates BCAA catabolism by inactivating BCKDH through phosphorylation.
• Controls the flux of BCAAs into the TCA cycle, impacting energy production.
• Mutations in BCKDH or its kinase can cause maple syrup urine disease, a severe metabolic disorder.
• BCKDK is essential for embryonic development and TCA cycle regulation.
• Altered BCKDK activity is implicated in cancer metabolism and neurological disorders.
• The kinase is a member of a unique mitochondrial protein kinase family with therapeutic potential.
• Its activity is modulated by metabolic intermediates like alpha-ketoisovalerate.
• Studying GO:0047323 aids in understanding mitochondrial signaling and metabolic integration.
Molecular Mechanism of [3-methyl-2-oxobutanoate dehydrogenase (acetyl-transferring)] kinase activity
Substrate Recognition and Binding
In simple terms: The kinase finds and attaches to its target protein.
BCKDK specifically recognizes the E1 alpha subunit of the BCKDH complex. This interaction is mediated by structural elements unique to the dehydrogenase, allowing the kinase to phosphorylate a specific serine residue (Ser293 in humans) within the E1 alpha subunit. The binding is essential for the subsequent phosphorylation event that inactivates the complex.
Catalytic Phosphorylation
In simple terms: The kinase transfers a phosphate group from ATP to the target protein.
Once bound, BCKDK catalyzes the transfer of the gamma-phosphate from ATP to the hydroxyl group of the target serine residue on the E1 alpha subunit. This reaction produces ADP and O-phospho-L-seryl-[3-methyl-2-oxobutanoate dehydrogenase], as defined by GO:0047323. The phosphorylation induces conformational changes that inhibit the dehydrogenase activity.
Inactivation of BCKDH Complex
In simple terms: Phosphorylation turns off the BCKDH enzyme, stopping BCAA breakdown.
Phosphorylation of the E1 alpha subunit by BCKDK leads to inactivation of the entire BCKDH complex. This prevents the oxidative decarboxylation of branched-chain alpha-ketoacids, thereby reducing the flux of BCAAs into the TCA cycle. This regulatory mechanism is crucial for maintaining BCAA homeostasis.
Regulation by Metabolic Intermediates
In simple terms: Small molecules can tweak the kinase's activity.
The activity of BCKDK can be modulated by metabolic intermediates. For example, alpha-ketoisovalerate, a BCAA metabolite, has been shown to stimulate pyruvate dehydrogenase kinase, a related kinase, suggesting that similar mechanisms may regulate BCKDK. This feedback regulation ensures that BCAA oxidation is adjusted to metabolic demands.
Role in Mitochondrial Energy Metabolism
In simple terms: The kinase helps balance energy production from different fuels.
BCKDK regulates the TCA cycle by controlling BCKDH activity. In the absence of PDK family members, BCKDK can also regulate pyruvate dehydrogenase complex (PDC) activity, demonstrating cross-talk between BCAA and glucose oxidation pathways. This integration is vital for metabolic flexibility.
Key Genes Involved in GO:0047323 [3-methyl-2-oxobutanoate dehydrogenase (acetyl-transferring)] kinase activity
The following genes and proteins are key players in the regulation and function of GO:0047323.
| Gene | Major Role | Research Relevance |
|---|---|---|
| BCKDK | Encodes the kinase that phosphorylates BCKDH | Central to GO:0047323; target for metabolic studies |
| BCKDHA | E1 alpha subunit of BCKDH; substrate of BCKDK | Mutations cause maple syrup urine disease |
| BCKDHB | E1 beta subunit of BCKDH | Forms the E1 heterotetramer with BCKDHA |
| DBT | Dihydrolipoamide branched chain transacylase E2 | Core component of BCKDH complex |
| DLD | Dihydrolipoamide dehydrogenase E3 | Shared with other dehydrogenase complexes |
| PDK1 | Pyruvate dehydrogenase kinase 1 | Related kinase; regulates PDC |
| PDK2 | Pyruvate dehydrogenase kinase 2 | Related kinase; regulates PDC |
| PDK3 | Pyruvate dehydrogenase kinase 3 | Related kinase; regulates PDC |
| PDK4 | Pyruvate dehydrogenase kinase 4 | Related kinase; regulates PDC |
| PDHA1 | E1 alpha subunit of PDC | Substrate of PDK; parallels BCKDH regulation |
| PDHB | E1 beta subunit of PDC | Component of PDC |
| DLAT | Dihydrolipoamide acetyltransferase E2 of PDC | Component of PDC |
| SLC7A5 | L-type amino acid transporter | Imports BCAAs; linked to BCAA metabolism |
| SLC3A2 | Heavy chain of amino acid transporter | Partners with SLC7A5 |
| BCAT1 | Branched-chain amino acid transaminase 1 | First step in BCAA catabolism |
| BCAT2 | Branched-chain amino acid transaminase 2 | Mitochondrial isoform |
| KARS | Lysyl-tRNA synthetase | Potential off-target in BCAA-related studies |
How Is [3-methyl-2-oxobutanoate dehydrogenase (acetyl-transferring)] kinase activity Regulated?
The activity of GO:0047323 is regulated at multiple levels. The expression of BCKDK is controlled by metabolic and hormonal signals, and its activity can be modulated by phosphorylation and by binding to metabolic intermediates. For instance, alpha-ketoisovalerate stimulates related kinases, suggesting a feedback loop where BCAA metabolites influence kinase activity. Additionally, BCKDK activity is integrated with mitochondrial energy status, as it can regulate PDC in the absence of PDK family members during embryonic development. This complex regulation ensures that BCAA catabolism is finely tuned to cellular needs.
[3-methyl-2-oxobutanoate dehydrogenase (acetyl-transferring)] kinase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| BCKDK | Maple syrup urine disease, cancer, neurodevelopmental disorders | Knockout mouse, patient-derived cells |
| BCKDHA | Maple syrup urine disease | Point mutation knock-in mice |
| BCKDHB | Maple syrup urine disease | Knockout cell lines |
| DBT | Maple syrup urine disease | CRISPR knock-in of patient mutations |
| PDHA1 | Pyruvate dehydrogenase deficiency | Knockout models to study cross-talk |
Maple Syrup Urine Disease (MSUD)
Maple syrup urine disease is an inherited metabolic disorder caused by mutations in the BCKDH complex, leading to accumulation of BCAAs and their toxic metabolites. While MSUD is primarily due to defects in BCKDHA, BCKDHB, or DBT, dysregulation of BCKDK activity can also contribute to the disease phenotype by altering the phosphorylation state of BCKDH. Understanding GO:0047323 is therefore relevant for diagnosing and managing MSUD.
Cancer Metabolism
Altered BCAA metabolism is a hallmark of several cancers. BCKDK overexpression has been observed in some cancers, leading to increased BCAA catabolism and supporting tumor growth. The kinase activity defined by GO:0047323 thus represents a potential therapeutic target in oncology.
Neurological Disorders
BCAA dysregulation has been implicated in neurological conditions such as autism and epilepsy. BCKDK mutations have been linked to neurodevelopmental disorders, highlighting the importance of GO:0047323 in brain function.
From [3-methyl-2-oxobutanoate dehydrogenase (acetyl-transferring)] kinase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| What is the effect of BCKDK loss on BCAA levels? | BCKDK knockout cell lines and mice |
| How does a specific BCKDK mutation affect kinase activity? | Point mutation knock-in via CRISPR |
| Can we tag BCKDK to study its localization? | Knock-in of fluorescent or epitope tags |
| What happens when BCKDK is overexpressed? | Overexpression cell lines and transgenic mice |
| How does BCKDK regulate PDC in the absence of PDKs? | Double knockout models (BCKDK/PDK) |
| Can we screen for modifiers of BCKDK activity? | CRISPR library screening |
How to Study the [3-methyl-2-oxobutanoate dehydrogenase (acetyl-transferring)] kinase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| In vitro kinase assay | Phosphorylation of BCKDH by BCKDK | Direct measurement of GO:0047323 activity |
| Western blot with phospho-specific antibodies | Phosphorylation state of BCKDH E1 alpha | Monitoring kinase activity in cells |
| LC-MS metabolomics | BCAA and metabolite levels | Assessing metabolic impact of kinase activity |
| CRISPR knockout | Loss of BCKDK function | Studying physiological roles |
| CRISPR knock-in | Introduction of specific mutations | Modeling disease-associated variants |
| Co-immunoprecipitation | Protein-protein interactions | Identifying binding partners |
| RNA-seq | Transcriptional changes | Global effects of BCKDK manipulation |
| Seahorse assay | Mitochondrial respiration | Evaluating metabolic flux |
Kinase Activity Assays
To directly measure GO:0047323, researchers can use in vitro kinase assays with recombinant BCKDK and BCKDH as substrates, followed by detection of phosphorylated serine residues using specific antibodies or mass spectrometry.
Metabolic Profiling
Metabolomics approaches, such as LC-MS, can quantify BCAA levels and their metabolites in cells or tissues with altered BCKDK expression, providing insights into the functional consequences of the kinase activity.
Genetic Knockout and Knock-in Models
CRISPR/Cas9-mediated knockout or knock-in of BCKDK or BCKDH subunits allows researchers to study the physiological roles of GO:0047323 in cell lines and animal models.
Protein-Protein Interaction Studies
Co-immunoprecipitation and proximity ligation assays can reveal how BCKDK interacts with BCKDH and other regulatory proteins, shedding light on the molecular mechanisms of GO:0047323.
How CRISPR Can Be Used to Study GO:0047323 [3-methyl-2-oxobutanoate dehydrogenase (acetyl-transferring)] kinase activity
Knockout
CRISPR/Cas9-mediated knockout of BCKDK can abolish GO:0047323 activity, leading to constitutive activation of BCKDH and increased BCAA catabolism. Such models are valuable for studying the consequences of uncontrolled BCAA oxidation in metabolic and neurological disorders.
Point Mutation
Introducing specific point mutations in BCKDK (e.g., in the catalytic domain) via CRISPR can help dissect the kinase's substrate specificity and regulation. These models mimic naturally occurring mutations and can reveal structure-function relationships.
Knock-in
Knock-in of tagged BCKDK (e.g., FLAG or GFP) allows for real-time tracking of the kinase's localization and interactions. This approach is useful for understanding how BCKDK is targeted to mitochondria and how it interacts with BCKDH.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of BCKDK can increase GO:0047323 activity, leading to BCKDH inhibition and reduced BCAA catabolism. This is relevant for cancer models where BCKDK is overexpressed.
How EDITGENE Supports [3-methyl-2-oxobutanoate dehydrogenase (acetyl-transferring)] kinase activity Research
Researchers studying [3-methyl-2-oxobutanoate dehydrogenase (acetyl-transferring)] kinase activity-related genes often need to determine whether a candidate gene is causally involved in metabolic regulation, disease progression, or therapeutic response. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this discovery process.
Contact EDITGENE today to design your custom CRISPR model for [3-methyl-2-oxobutanoate dehydrogenase (acetyl-transferring)] kinase activity research.
Frequently Asked Questions About [3-methyl-2-oxobutanoate dehydrogenase (acetyl-transferring)] kinase activity
What is GO:0047323?
GO:0047323 is a Gene Ontology molecular function term that describes the kinase activity responsible for phosphorylating the E1 alpha subunit of the branched-chain alpha-ketoacid dehydrogenase complex (BCKDH), thereby inactivating it.
What genes are involved in GO:0047323?
The primary gene encoding the kinase is BCKDK. The substrate is encoded by BCKDHA (E1 alpha subunit of BCKDH). Other related genes include BCKDHB, DBT, and DLD, which form the BCKDH complex.
What is the function of BCKDK?
BCKDK phosphorylates and inactivates the BCKDH complex, reducing the breakdown of branched-chain amino acids. This regulation is crucial for metabolic homeostasis.
How is BCKDK activity regulated?
BCKDK activity can be modulated by metabolic intermediates such as alpha-ketoisovalerate and by cross-talk with other mitochondrial kinases like PDK.
What diseases are associated with BCKDK mutations?
Mutations in BCKDK or its substrate can lead to maple syrup urine disease, neurodevelopmental disorders, and are implicated in cancer metabolism.
What is the role of BCKDK in cancer?
BCKDK overexpression can promote BCAA catabolism, supporting tumor growth in some cancers. Targeting BCKDK is being explored as a therapeutic strategy.
How can I study GO:0047323 in the lab?
Common methods include in vitro kinase assays, phospho-specific Western blots, metabolomics, and CRISPR-based genetic models.
What CRISPR models are available for BCKDK?
EDITGENE offers knockout, point mutation, knock-in, and overexpression models for BCKDK and related genes, as well as CRISPR library screening services.
Is BCKDK related to pyruvate dehydrogenase kinase?
Yes, BCKDK belongs to the same mitochondrial alpha-ketoacid dehydrogenase kinase family as PDK, and they share regulatory mechanisms.
What are the synonyms for GO:0047323?
Synonyms include BCKD kinase activity, branched-chain alpha-ketoacid dehydrogenase kinase activity, and STK2.
Conclusion
GO:0047323 represents a critical molecular function in BCAA metabolism, with far-reaching implications for metabolic disorders, cancer, and neurodevelopment. Understanding its regulation and downstream effects provides opportunities for therapeutic intervention. EDITGENE's CRISPR services empower researchers to dissect this pathway with precision and efficiency.
References
- 1. Robertson JG et al.. 1986. Effects of alpha-ketoisovalerate on bovine heart pyruvate dehydrogenase complex and pyruvate dehydrogenase kinase.. J Biol Chem 261(1):76-81 PMID: 3941088
- 2. Harris RA et al.. 1995. A new family of protein kinases--the mitochondrial protein kinases.. Adv Enzyme Regul 35:147-62 PMID: 7572341
- 3. Popov KM et al.. 1997. Mitochondrial alpha-ketoacid dehydrogenase kinases: a new family of protein kinases.. Adv Second Messenger Phosphoprotein Res 31:105-11 PMID: 9344245
- 4. Robertson JG et al.. 1990. Bovine heart pyruvate dehydrogenase kinase stimulation by alpha-ketoisovalerate.. J Biol Chem 265(28):16814-20 PMID: 2211597
- 5. Popov KM et al.. 1991. Purification and comparative study of the kinases specific for branched chain alpha-ketoacid dehydrogenase and pyruvate dehydrogenase.. Protein Expr Purif 2(4):278-86 PMID: 1821799
- 6. Heinemann-Yerushalmi L et al.. 2021. BCKDK regulates the TCA cycle through PDC in the absence of PDK family during embryonic development.. Dev Cell 56(8):1182-1194.e6 PMID: 33773101
- 7. Harris RA et al.. 1997. Studies on the regulation of the mitochondrial alpha-ketoacid dehydrogenase complexes and their kinases.. Adv Enzyme Regul 37:271-93 PMID: 9381974
